EP4464708A1 — New contrast agents for use in diagnostic imaging
Assigned to Bayer AG · Expires 2024-11-20 · 1y expired
What this patent protects
The present invention relates to new manganese (Mn 2+ ) chelate compounds, to methods of preparing said compounds, to the use of said compounds as contrast agents in diagnostic imaging such as magnetic resonance imaging (MRI) and to their use in a mammalian body.
USPTO Abstract
The present invention relates to new manganese (Mn 2+ ) chelate compounds, to methods of preparing said compounds, to the use of said compounds as contrast agents in diagnostic imaging such as magnetic resonance imaging (MRI) and to their use in a mammalian body.
Drugs covered by this patent
- Elucirem (GADOPICLENOL) · Guerbet
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.